News

GV Backs Hair Loss Biotech out of UCLA with PhII set for mid-2024

March 1, 2024

Pelage Pharmaceuticals, a Los Angeles-based hair loss biotech based on research out of UCLA, has reeled in a $16.75 million Series A and plans to start a mid-stage trial later this year.

See full article below;

Read more about GV Backs Hair Loss Biotech out of UCLA with PhII set for mid-2024

Immpact Bio Awarded $8million CIRM Grant

March 1, 2024

Please see full article on PR News below:

Read more about Immpact Bio Awarded $8million CIRM Grant

LABEST 2024 Early Bird On Sale Now

February 21, 2024

Early Bird Tickets to LABEST 2024 are now available.

Read more about LABEST 2024 Early Bird On Sale Now

The Lancet Neurology features UCLA researcher Rhonda Voskuhl

February 6, 2024

UCLA Researcher Rhonda Voskuhl featured in neurology journal

&n

Read more about The Lancet Neurology features UCLA researcher Rhonda Voskuhl

UCLA acquires L.A.’s former Westside Pavilion transform into UCLA Research Park

January 3, 2024

Rendering of old Westside Pavillion

Read more about UCLA acquires L.A.’s former Westside Pavilion transform into UCLA Research Park

UCLA TDG Innovation Magazine Winter 2023

December 14, 2023

UCLA TDG Innovation Magazine Winter 2023 Highlights

* UCLA TDG by the Numbers

* UCLA Ranks #1 in Scientific Publications in the LA Region

* Equatic named one of TIME Magazine's Best Inventions of 2023

* FDA Fast Track for ImmPact Bio therapeutic

* Autobahn and UCLA

and more

READ MAGAZINE

Read more about UCLA TDG Innovation Magazine Winter 2023

Autobahn Labs Announces Key Licensing Milestones in Alliances with Early University Partners

November 21, 2023

PALO ALTO, CA, USA, November 14, 2023 – Autobahn Labs, an early-stage drug discovery incubator, announced today that it had executed exclusive license agreements to foundational technologies in its collaborations with the Los Angeles and San Francisco campuses of the University of California. The objective of Autobahn’s collaborations with its academic partners is to identify academic research programs targeting important unmet medical needs and to advance their commercialization in companies it launches.